Concerta (Methylphenidate) Safety in Pregnancy

Overall Safety Profile

Methylphenidate overall does not seem to be associated with major congenital malformations or other significant adverse obstetrical or developmental outcomes, according to the American College of Obstetricians and Gynecologists 1

There is a possible increased risk for cardiac malformations (OR 1.59; 95% CI 1.02-2.49), but this risk appears to be small with an absolute risk of only 1.7%, as reported by the American Journal of Obstetrics and Gynecology 1
There is a possible increased risk for gastroschisis (aOR 3.0; 95% CI 1.2-7.4), though the absolute risk remains extremely small given the population prevalence of only 0.05%, as found by the American College of Obstetricians and Gynecologists 1
Possible small increased risk for preeclampsia (aRR 1.29; 95% CI 1.11-1.49), though other studies have not consistently found this association, according to the American College of Obstetricians and Gynecologists 1
Possible small increased risk for preterm birth (aOR 1.3; 95% CI 1.1-1.6), but the magnitude of risk is modest, as reported by the American College of Obstetricians and Gynecologists 1
Possible increased risk for spontaneous abortion, though confounding by indication cannot be ruled out, as noted by the American College of Obstetricians and Gynecologists 1
Possible increased risk for poor neonatal adaptation (23.6% vs 13.5%; P = 0.05), though this difference was only marginally statistically significant, according to the American College of Obstetricians and Gynecologists 1
Possible increased risk for NICU admission (aOR 1.5; 95% CI 1.3-1.7), as found by the American College of Obstetricians and Gynecologists 1

The treating physician should weigh the need for treatment against the severity of ADHD symptoms and functional impairment, as recommended by the American Academy of Pediatrics 1

Monitor for signs of preeclampsia and preterm labor throughout pregnancy, as advised by the American College of Obstetricians and Gynecologists 1
Monitor infants for poor neonatal adaptation, including irritability, feeding difficulties, and need for NICU admission, according to the American Academy of Pediatrics 1

Confounding by indication is a major limitation across all observational studies—women with ADHD may have baseline increased risks independent of medication use, as noted by the American College of Obstetricians and Gynecologists 1

The American College of Obstetricians and Gynecologists recommends that a pregnant woman with ADHD can continue Concerta (methylphenidate) 36mg if the medication is required for her daily functioning, as the documented risks are very low and do not outweigh the benefits of treatment for moderate to severe ADHD 2
The American College of Obstetricians and Gynecologists guidelines state that the magnitude of documented risks is very low and treatment with medications should not be stopped if they are required for the daily functioning of the pregnant person 2

Discontinuing methylphenidate during pregnancy can lead to worse mental health outcomes and significant impairments in functioning in the pregnant individual, which may subsequently have negative impacts on the developing fetus 3
Untreated ADHD itself has been shown to be associated with increased risks for spontaneous abortion and preterm birth, meaning the disease itself poses risks independent of medication 3

The American College of Obstetricians and Gynecologists recommends continuing methylphenidate at the current effective dose if required for daily functioning 2
If the patient can function adequately without medication, consider a trial of gradual discontinuation before pregnancy 2
If unable to discontinue, continue current medication or reduce to lowest effective dose, or consider intermittent use 2
Monitor pregnancy carefully: fetal growth, blood pressure checks for preeclampsia, and ensure appropriate weight gain 2
Maintain therapeutic dose at delivery and during breastfeeding, as methylphenidate is compatible with breastfeeding 2
Monitor infant for irritability, insomnia, feeding difficulties, and poor neonatal adaptation 2
Ensure infant is gaining weight appropriately and meeting developmental milestones 2
Methylphenidate is compatible with breastfeeding (Hale lactation risk category L3) 3
Monitor infant for irritability, insomnia, and feeding difficulties while breastfeeding 3

Initiate immediate‑release methylphenidate at 5–10 mg twice daily, or use extended‑release formulations at 18–36 mg once daily in the morning for pregnant patients requiring treatment, following standard ADHD dosing principles. 4

Aim for symptom control rather than arbitrarily reducing the dose; the target is the lowest effective dose that maintains adequate daily functioning. 4

A large, well‑controlled observational study found no increased risk of adverse long‑term neurodevelopmental outcomes—including psychiatric disorders, visual or auditory impairments, epilepsy, seizures, or growth impairment—in children exposed to methylphenidate in utero. (High‑quality evidence) 4